Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib Upon Progression to Chemotherapy and Next Generation Hormonal Agents: a Phase II Study

NCT05265988 is registered in ClinicalTrials.gov with Alfredo Berruti as lead sponsor.

NCT NCT05265988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05265988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib Upon Progression to Chemotherapy and Next Generation Hormonal Agents: a Phase II Study
Lead sponsor
Alfredo Berruti
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2021
Completion date
June 29, 2024
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma prostate